Efficacy and safety of hyperbaric oxygen therapy for vascular cognitive impairment: a meta-analysis_West China Medical Journal

Authors：

LIU Wenxiu ¹ , WANG Ming ² , PENG Xiaoling ³ ,  ZENG Xianrong ^1,3

1. School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, P. R. China;
2. Department of Intensive Care Unit, Mianyang Central Hospital, Mianyang, Sichuan 621000, P. R. China;
3. Hyperbaric Oxygen Therapy Center, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, P. R. China;

Corresponding author：

ZENG Xianrong, Email: 570574804@qq.com

Keywords：

Vascular cognitive impairment; hyperbaric oxygen; randomized controlled trials; meta-analysis

DOI：

10.7507/1002-0179.202111008

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To conduct a meta-analysis of the evidence on the efficacy and safety of hyperbaric oxygen therapy for vascular cognitive impairment. Methods China National Knowledge Infrastructure, Chongqing VIP, Wanfang, SinoMed, PubMed, Embase, CINHAL, Cochrance Library were searched for all literatures on randomized controlled trials of hyperbaric oxygen therapy for vascular cognitive impairment from the establishment of databases to May 2022. Literature screening was performed by Endnote X9 software, and meta-analysis was performed by RevMan 5.4.1 software. Results A total of 36 papers were included, with 3093 patients, including 1549 cases in the observation group (hyperbaric oxygen combined with drug treatment) and 1544 cases in the control group (drug treatment alone). Compared with the control group, the effective rate of the observation group [relative risk=1.23, 95% confidence interval (CI) (1.15, 1.30), P<0.00001], the scores of Mini Mental Status Examination [mean difference (MD)=3.19, 95%CI (2.66, 3.73), P<0.00001], and the scores of Montreal Cognitive Assessment [MD=2.98, 95%CI (2.07, 3.89), P<0.00001] were better than those of the control group. There was no significant difference in adverse reactions between the observation group and the control group (P>0.05). For the scores of Activities of Daily Living, subgroup analysis showed high heterogeneity among studies, so pooled analysis was not performed. Conclusion Compared with drug therapy alone, hyperbaric oxygen combined with drug therapy can improve the cognitive function of patients with vascular cognitive impairment to a certain extent without increasing adverse reactions.

Citation： LIU Wenxiu, WANG Ming, PENG Xiaoling, ZENG Xianrong. Efficacy and safety of hyperbaric oxygen therapy for vascular cognitive impairment: a meta-analysis. West China Medical Journal, 2022, 37(6): 863-874. doi: 10.7507/1002-0179.202111008 Copy

1.	中国医师协会神经内科分会认知障碍专业委员会, 《中国血管性认知障碍诊治指南》编写组. 2019 年中国血管性认知障碍诊治指南. 中华医学杂志, 2019, 99(35): 2737-2744.
2.	O’Brien JT, Wiseman R, Burton EJ, et al. Cognitive associations of subcortical white matter lesions in older people. Ann N Y Acad Sci, 2002, 977: 436-444.
3.	Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2011, 42(9): 2672-2713.
4.	Skrobot OA, Black SE, Chen C, et al. Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement, 2018, 14(3): 280-292.
5.	Shah H, Albanese E, Duggan C, et al. Research priorities to reduce the global burden of dementia by 2025. Lancet Neurol, 2016, 15(12): 1285-1294.
6.	Larsson SC, Markus HS. Does treating vascular risk factors prevent dementia and Alzheimer’s disease? A systematic review and meta-analysis. J Alzheimers Dis, 2018, 64(2): 657-668.
7.	Smith EE, Barber P, Field TS, et al. Canadian consensus conference on diagnosis and treatment of dementia (CCCDTD)5: guidelines for management of vascular cognitive impairment. Alzheimers Dement (N Y), 2020, 6(1): e12056.
8.	Ismail Z, Black SE, Camicioli R, et al. Recommendations of the 5th Canadian consensus conference on the diagnosis and treatment of dementia. Alzheimers Dement, 2020, 16(8): 1182-1195.
9.	王水平, 陶珍, 丁素菊, 等. 高压氧并盐酸多奈哌齐治疗血管性痴呆的疗效观察. 中华物理医学与康复杂志, 2009, 31(7): 478-480.
10.	荆宏建, 罗松平, 张津华. 高压氧联合多奈哌齐治疗血管性痴呆伴失语的观察. 实用老年医学, 2009, 23(6): 475-476.
11.	吴泳, 梁雁, 黄丹丹. 奥拉西坦联合高压氧治疗血管性痴呆疗效观察. 中国实用神经疾病杂志, 2010, 13(7): 13-14.
12.	陈士东. 奥拉西坦与高压氧联合治疗血管性痴呆 41 例疗效观察. 医学理论与实践, 2011, 24(12): 1425-1426.
13.	王松林, 翟鲁辉. 高压氧与奥拉西坦联合治疗血管性痴呆 40 例疗效观察. 中国医药指南, 2011, 9(32): 312-313.
14.	邓晓玲, 汪健, 赵斌. 高压氧对血管性痴呆患者认知和生活能力及血液流变学的影响. 中国康复, 2011, 26(2): 96-97.
15.	卜桂文. 联合应用奥拉西坦与高压氧对 96 例血管性痴呆病人的临床疗效观察. 心理医生(下半月版), 2012(10): 80.
16.	梁花敏, 范学文. 高压氧联合盐酸多奈哌齐干预轻度血管性认知障碍疗效观察. 宁夏医科大学学报, 2012, 34(3): 276-278.
17.	祁文君, 张义, 罗亨勤, 等. 奥拉西坦联合高压氧治疗轻度血管性认知障碍的疗效观察. 西南国防医药, 2012, 22(12): 1350-1352.
18.	宋玉华. 奥拉西坦与高压氧联合治疗血管性痴呆 63 例疗效观察. 大家健康(学术版), 2012(6): 5-7.
19.	夏希愿. 高压氧治疗血管性痴呆的疗效观察. 亚太传统医药, 2012, 8(1): 84-85.
20.	姜薇薇, 陈艺敏. 高压氧联合奥拉西坦治疗血管性认知功能障碍的疗效观察. 中国医学工程, 2013, 21(12): 131.
21.	李文. 高压氧联合奥拉西坦治疗血管性痴呆 36 例疗效分析. 中国医药科学, 2013, 3(4): 63-64.
22.	唐龙冲, 郑湛云, 李新鸿, 等. 高压氧对血管性痴呆患者认知的影响研究. 中国医药指南, 2013(13): 92.
23.	刘丽, 高焱. 奥拉西坦联合高压氧治疗血管性痴呆疗效观察. 中国民康医学, 2015(2): 80-81.
24.	孙薇, 杨建波, 徐金凤, 等. 丁苯酞软胶囊联合高压氧治疗老年血管性痴呆的临床疗效观察. 实用心脑肺血管病杂志, 2015, 23(9): 62-64.
25.	许玫. 分析奥拉西坦与高压氧在血管性痴呆治疗中的应用. 中国继续医学教育, 2015(30): 190-191.
26.	赵鹏翔. 丁苯酞软胶囊联合高压氧治疗血管性痴呆疗效观察. 基层医学论坛, 2015(5): 610-611.
27.	柳志一. 奥拉西坦与高压氧联合治疗血管性痴呆的临床效果分析. 中国医疗器械信息, 2016, 22(18): 87-88.
28.	乔宇. 奥拉西坦联合高压氧治疗血管性痴呆患者的临床疗效. 中国药物经济学, 2016, 11(6): 46-48.
29.	沈雷. 高压氧联合盐酸多奈哌齐治疗轻中度血管性认知障碍患者的疗效观察. 中国药物经济学, 2016, 11(9): 92-93.
30.	吴辉丽, 唐妍妍. 丁苯酞联合高压氧治疗血管性痴呆疗效分析. 现代医药卫生, 2016, 32(23): 3696-3697.
31.	赵静华. 丁苯酞联合高压氧治疗血管性认知功能障碍患者的疗效观察. 心理医生, 2016, 22(11): 26-28.
32.	周莎莎. 盐酸多奈哌齐联合高压氧治疗脑卒中后血管性认知障碍的效果观察. 中国实用神经疾病杂志, 2016, 19(19): 63-64.
33.	李培忠. 高压氧联合盐酸多奈哌齐干预轻度血管性认知障碍的效果观察. 临床合理用药杂志, 2017, 10(5): 27-28.
34.	薛标强. 丁苯酞联合高压氧治疗老年血管性痴呆的临床效果观察. 中国处方药, 2017, 15(10): 66-67.
35.	周爱华. 血管性痴呆应用奥拉西坦与高压氧联合治疗的效果研究. 世界临床医学, 2017, 11(1): 53,55.
36.	陈金华. 奥拉西坦与高压氧治疗血管性痴呆临床探讨. 中国卫生标准管理, 2018, 9(17): 71-72.
37.	姜广亚, 娄季宇, 杨霄鹏, 等. 盐酸多奈哌齐联合高压氧治疗血管性认知障碍疗效观察. 中国实用神经疾病杂志, 2019, 22(22): 2498-2503.
38.	李紫丞. 高压氧联合盐酸多奈哌齐及美金刚治疗老年血管性痴呆患者的疗效分析. 首都食品与医药, 2020, 27(8): 53.
39.	冯子凌, 刘秀红, 郭明霞. 丁苯酞软胶囊联合高压氧治疗早期血管性认知障碍的疗效观察. 中国实用医刊, 2021, 48(19): 73-75.
40.	郭留芹, 赵晓玲, 危保松. 高压氧联合多奈哌齐和盐酸美金刚治疗血管性认知障碍的效果观察. 中国实用医刊, 2021, 48(21): 59-62.
41.	蒋芳况, 王杨, 王丽, 等. 高压氧联合有氧运动治疗老年轻度血管性痴呆的疗效观察. 国际老年医学杂志, 2021, 42(5): 275-278.
42.	刘星. 高压氧+盐酸多奈哌齐干预轻度血管性认知障碍的临床效果. 中国现代药物应用, 2021, 15(14): 163-165.
43.	荀警杰. 高压氧+盐酸多奈哌齐联用治疗轻度血管性认知障碍的临床效果. 中国实用医药, 2021, 16(30): 62-64.
44.	张蕊. 奥拉西坦与高压氧联合治疗血管性痴呆的应用与效果评析. 中国现代药物应用, 2021, 15(1): 92-94.
45.	Li X, Li J, Yang X, et al. Hyperbaric-oxygen therapy improves survival and functional outcome of acute severe intracerebral hemorrhage. Arch Med Res, 2017, 48(7): 638-652.
46.	Al-Waili NS, Butler GJ, Beale J, et al. Hyperbaric oxygen in the treatment of patients with cerebral stroke, brain trauma, and neurologic disease. Adv Ther, 2005, 22(6): 659-678.
47.	Rockswold SB, Rockswold GL, Vargo JM, et al. Effects of hyperbaric oxygenation therapy on cerebral metabolism and intracranial pressure in severely brain injured patients. J Neurosurg, 2001, 94(3): 403-411.
48.	Zhou Y, Dong Q, Pan Z, et al. Hyperbaric oxygen improves functional recovery of the injured spinal cord by inhibiting inflammation and glial scar formation. Am J Phys Med Rehabil, 2019, 98(10): 914-920.
49.	Huang X, Liang P, Jiang B, et al. Hyperbaric oxygen potentiates diabetic wound healing by promoting fibroblast cell proliferation and endothelial cell angiogenesis. Life Sci, 2020, 259: 118246.
50.	Yang Y, Wei H, Zhou X, et al. Hyperbaric oxygen promotes neural stem cell proliferation by activating vascular endothelial growth factor/extracellular signal-regulated kinase signaling after traumatic brain injury. Neuroreport, 2017, 28(18): 1232-1238.
51.	Hedetoft M, Polzik P, Olsen NV, et al. Neuronal nitric oxide inhibition attenuates the protective effect of HBO2 during cyanide poisoning. Undersea Hyperb Med, 2018, 45(3): 335-350.
52.	Thompson LW, Davis GC, Obrist WD, et al. Effects of hyperbaric oxygen on behavioral and physiological measures in elderly demented patients. J Gerontol, 1976, 31(1): 23-28.
53.	程媛媛, 张云东. 高压氧治疗血管性痴呆随机对照试验的 Meta 分析. 中国当代医药, 2016, 23(29): 16-19.

1. 中国医师协会神经内科分会认知障碍专业委员会, 《中国血管性认知障碍诊治指南》编写组. 2019 年中国血管性认知障碍诊治指南. 中华医学杂志, 2019, 99(35): 2737-2744.
2. O’Brien JT, Wiseman R, Burton EJ, et al. Cognitive associations of subcortical white matter lesions in older people. Ann N Y Acad Sci, 2002, 977: 436-444.
3. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2011, 42(9): 2672-2713.
4. Skrobot OA, Black SE, Chen C, et al. Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement, 2018, 14(3): 280-292.
5. Shah H, Albanese E, Duggan C, et al. Research priorities to reduce the global burden of dementia by 2025. Lancet Neurol, 2016, 15(12): 1285-1294.
6. Larsson SC, Markus HS. Does treating vascular risk factors prevent dementia and Alzheimer’s disease? A systematic review and meta-analysis. J Alzheimers Dis, 2018, 64(2): 657-668.
7. Smith EE, Barber P, Field TS, et al. Canadian consensus conference on diagnosis and treatment of dementia (CCCDTD)5: guidelines for management of vascular cognitive impairment. Alzheimers Dement (N Y), 2020, 6(1): e12056.
8. Ismail Z, Black SE, Camicioli R, et al. Recommendations of the 5th Canadian consensus conference on the diagnosis and treatment of dementia. Alzheimers Dement, 2020, 16(8): 1182-1195.
9. 王水平, 陶珍, 丁素菊, 等. 高压氧并盐酸多奈哌齐治疗血管性痴呆的疗效观察. 中华物理医学与康复杂志, 2009, 31(7): 478-480.
10. 荆宏建, 罗松平, 张津华. 高压氧联合多奈哌齐治疗血管性痴呆伴失语的观察. 实用老年医学, 2009, 23(6): 475-476.
11. 吴泳, 梁雁, 黄丹丹. 奥拉西坦联合高压氧治疗血管性痴呆疗效观察. 中国实用神经疾病杂志, 2010, 13(7): 13-14.
12. 陈士东. 奥拉西坦与高压氧联合治疗血管性痴呆 41 例疗效观察. 医学理论与实践, 2011, 24(12): 1425-1426.
13. 王松林, 翟鲁辉. 高压氧与奥拉西坦联合治疗血管性痴呆 40 例疗效观察. 中国医药指南, 2011, 9(32): 312-313.
14. 邓晓玲, 汪健, 赵斌. 高压氧对血管性痴呆患者认知和生活能力及血液流变学的影响. 中国康复, 2011, 26(2): 96-97.
15. 卜桂文. 联合应用奥拉西坦与高压氧对 96 例血管性痴呆病人的临床疗效观察. 心理医生(下半月版), 2012(10): 80.
16. 梁花敏, 范学文. 高压氧联合盐酸多奈哌齐干预轻度血管性认知障碍疗效观察. 宁夏医科大学学报, 2012, 34(3): 276-278.
17. 祁文君, 张义, 罗亨勤, 等. 奥拉西坦联合高压氧治疗轻度血管性认知障碍的疗效观察. 西南国防医药, 2012, 22(12): 1350-1352.
18. 宋玉华. 奥拉西坦与高压氧联合治疗血管性痴呆 63 例疗效观察. 大家健康(学术版), 2012(6): 5-7.
19. 夏希愿. 高压氧治疗血管性痴呆的疗效观察. 亚太传统医药, 2012, 8(1): 84-85.
20. 姜薇薇, 陈艺敏. 高压氧联合奥拉西坦治疗血管性认知功能障碍的疗效观察. 中国医学工程, 2013, 21(12): 131.
21. 李文. 高压氧联合奥拉西坦治疗血管性痴呆 36 例疗效分析. 中国医药科学, 2013, 3(4): 63-64.
22. 唐龙冲, 郑湛云, 李新鸿, 等. 高压氧对血管性痴呆患者认知的影响研究. 中国医药指南, 2013(13): 92.
23. 刘丽, 高焱. 奥拉西坦联合高压氧治疗血管性痴呆疗效观察. 中国民康医学, 2015(2): 80-81.
24. 孙薇, 杨建波, 徐金凤, 等. 丁苯酞软胶囊联合高压氧治疗老年血管性痴呆的临床疗效观察. 实用心脑肺血管病杂志, 2015, 23(9): 62-64.
25. 许玫. 分析奥拉西坦与高压氧在血管性痴呆治疗中的应用. 中国继续医学教育, 2015(30): 190-191.
26. 赵鹏翔. 丁苯酞软胶囊联合高压氧治疗血管性痴呆疗效观察. 基层医学论坛, 2015(5): 610-611.
27. 柳志一. 奥拉西坦与高压氧联合治疗血管性痴呆的临床效果分析. 中国医疗器械信息, 2016, 22(18): 87-88.
28. 乔宇. 奥拉西坦联合高压氧治疗血管性痴呆患者的临床疗效. 中国药物经济学, 2016, 11(6): 46-48.
29. 沈雷. 高压氧联合盐酸多奈哌齐治疗轻中度血管性认知障碍患者的疗效观察. 中国药物经济学, 2016, 11(9): 92-93.
30. 吴辉丽, 唐妍妍. 丁苯酞联合高压氧治疗血管性痴呆疗效分析. 现代医药卫生, 2016, 32(23): 3696-3697.
31. 赵静华. 丁苯酞联合高压氧治疗血管性认知功能障碍患者的疗效观察. 心理医生, 2016, 22(11): 26-28.
32. 周莎莎. 盐酸多奈哌齐联合高压氧治疗脑卒中后血管性认知障碍的效果观察. 中国实用神经疾病杂志, 2016, 19(19): 63-64.
33. 李培忠. 高压氧联合盐酸多奈哌齐干预轻度血管性认知障碍的效果观察. 临床合理用药杂志, 2017, 10(5): 27-28.
34. 薛标强. 丁苯酞联合高压氧治疗老年血管性痴呆的临床效果观察. 中国处方药, 2017, 15(10): 66-67.
35. 周爱华. 血管性痴呆应用奥拉西坦与高压氧联合治疗的效果研究. 世界临床医学, 2017, 11(1): 53,55.
36. 陈金华. 奥拉西坦与高压氧治疗血管性痴呆临床探讨. 中国卫生标准管理, 2018, 9(17): 71-72.
37. 姜广亚, 娄季宇, 杨霄鹏, 等. 盐酸多奈哌齐联合高压氧治疗血管性认知障碍疗效观察. 中国实用神经疾病杂志, 2019, 22(22): 2498-2503.
38. 李紫丞. 高压氧联合盐酸多奈哌齐及美金刚治疗老年血管性痴呆患者的疗效分析. 首都食品与医药, 2020, 27(8): 53.
39. 冯子凌, 刘秀红, 郭明霞. 丁苯酞软胶囊联合高压氧治疗早期血管性认知障碍的疗效观察. 中国实用医刊, 2021, 48(19): 73-75.
40. 郭留芹, 赵晓玲, 危保松. 高压氧联合多奈哌齐和盐酸美金刚治疗血管性认知障碍的效果观察. 中国实用医刊, 2021, 48(21): 59-62.
41. 蒋芳况, 王杨, 王丽, 等. 高压氧联合有氧运动治疗老年轻度血管性痴呆的疗效观察. 国际老年医学杂志, 2021, 42(5): 275-278.
42. 刘星. 高压氧+盐酸多奈哌齐干预轻度血管性认知障碍的临床效果. 中国现代药物应用, 2021, 15(14): 163-165.
43. 荀警杰. 高压氧+盐酸多奈哌齐联用治疗轻度血管性认知障碍的临床效果. 中国实用医药, 2021, 16(30): 62-64.
44. 张蕊. 奥拉西坦与高压氧联合治疗血管性痴呆的应用与效果评析. 中国现代药物应用, 2021, 15(1): 92-94.
45. Li X, Li J, Yang X, et al. Hyperbaric-oxygen therapy improves survival and functional outcome of acute severe intracerebral hemorrhage. Arch Med Res, 2017, 48(7): 638-652.
46. Al-Waili NS, Butler GJ, Beale J, et al. Hyperbaric oxygen in the treatment of patients with cerebral stroke, brain trauma, and neurologic disease. Adv Ther, 2005, 22(6): 659-678.
47. Rockswold SB, Rockswold GL, Vargo JM, et al. Effects of hyperbaric oxygenation therapy on cerebral metabolism and intracranial pressure in severely brain injured patients. J Neurosurg, 2001, 94(3): 403-411.
48. Zhou Y, Dong Q, Pan Z, et al. Hyperbaric oxygen improves functional recovery of the injured spinal cord by inhibiting inflammation and glial scar formation. Am J Phys Med Rehabil, 2019, 98(10): 914-920.
49. Huang X, Liang P, Jiang B, et al. Hyperbaric oxygen potentiates diabetic wound healing by promoting fibroblast cell proliferation and endothelial cell angiogenesis. Life Sci, 2020, 259: 118246.
50. Yang Y, Wei H, Zhou X, et al. Hyperbaric oxygen promotes neural stem cell proliferation by activating vascular endothelial growth factor/extracellular signal-regulated kinase signaling after traumatic brain injury. Neuroreport, 2017, 28(18): 1232-1238.
51. Hedetoft M, Polzik P, Olsen NV, et al. Neuronal nitric oxide inhibition attenuates the protective effect of HBO2 during cyanide poisoning. Undersea Hyperb Med, 2018, 45(3): 335-350.
52. Thompson LW, Davis GC, Obrist WD, et al. Effects of hyperbaric oxygen on behavioral and physiological measures in elderly demented patients. J Gerontol, 1976, 31(1): 23-28.
53. 程媛媛, 张云东. 高压氧治疗血管性痴呆随机对照试验的 Meta 分析. 中国当代医药, 2016, 23(29): 16-19.

West China Medical Journal

Efficacy and safety of hyperbaric oxygen therapy for vascular cognitive impairment: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content